Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1356634
This article is part of the Research Topic The Future of Hematologic Malignancy Treatment: Novel Target Discovery and Epigenetic Drug Development View all 7 articles

Ubiquitin-Specific Peptidases in Lymphoma: A Path to Novel Therapeutics

Provisionally accepted
Maryam Samareh Maryam Samareh 1Shirin Tavakoli Shirin Tavakoli 1Aram Halimi Aram Halimi 2Shima Tavoosi Shima Tavoosi 3Amir Hossein Baghsheikhi Amir Hossein Baghsheikhi 4Abdolkarim T. Taheri Abdolkarim T. Taheri 2Mohammad Ahmadvand Mohammad Ahmadvand 1Mehdi Niloufari Mehdi Niloufari 2Javad Verdi Javad Verdi 1Soheila Rahgozar Soheila Rahgozar 3Seyed Alireza Mosavi-Jarrahi Seyed Alireza Mosavi-Jarrahi 2*Zahra Salehi Zahra Salehi 1*
  • 1 Tehran University of Medical Sciences, Tehran, Tehran, Iran
  • 2 Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • 3 University of Isfahan, Isfahan, Isfahan, Iran
  • 4 Islamic Azad University System, Tehran, Tehran, Iran

The final, formatted version of the article will be published soon.

    Background: Ubiquitin-specific peptidases (USPs), also known as deubiquitinating enzymes (DUBs), play a crucial role in maintaining cellular homeostasis by selectively removing ubiquitin molecules from targeted proteins. This process affects protein stability, subcellular localization, and activity, thereby influencing processes such as DNA repair, cell cycle regulation, and apoptosis. Abnormal USP activities have been linked to various diseases, including cancer.Emerging evidence in lymphoma highlights the significance of USPs in controlling signaling pathways related to cancer initiation and progression and presents them as potential therapeutic targets.Aim: To elucidate the multifaceted roles of ubiquitin-specific peptidases (USPs) in lymphoma.: This systematic review was conducted by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles published in English up to May 2023 were retrieved from PubMed, Web of Science, and Scopus. The inclusion criteria focused on studies investigating the role of USPs in lymphoma cancer, involving human subjects or relevant lymphoma cell lines, exploring molecular mechanisms and signaling pathways, and assessing diagnostic or prognostic value. Results: After the selection process, 23 studies were selected for analysis. USPs were found to affect various aspects of lymphoma development and progression. Specific USPs were identified with roles in cell cycle regulation, apoptosis modulation, drug resistance, DNA repair, and influence of key oncogenic pathways, such as B cell receptor (BCR) signaling. Conclusion: This systematic review underscores the emerging role of USPs in lymphoma and their potential as therapeutic targets. Inhibitors of USPs, like USP14 inhibitors, show promise in overcoming drug resistance. The dynamic interplay between USPs and lymphoma biology presents an exciting opportunity for future research and the development of more effective treatments for patients with lymphoma. Understanding the intricate functions of USPs in lymphoma offers new insights into potential therapeutic strategies, emphasizing the significance of these enzymes in the context of cancer biology.

    Keywords: Ubiquitin-specific peptidases, USPS, Cancer, and Lymphoma Cancer, Hematologialc malignancy

    Received: 15 Dec 2023; Accepted: 14 Oct 2024.

    Copyright: © 2024 Samareh, Tavakoli, Halimi, Tavoosi, Baghsheikhi, Taheri, Ahmadvand, Niloufari, Verdi, Rahgozar, Mosavi-Jarrahi and Salehi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Seyed Alireza Mosavi-Jarrahi, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Zahra Salehi, Tehran University of Medical Sciences, Tehran, 1417863181, Tehran, Iran

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.